The purpose of this study is to determine whether pharmacogenetic study predict Mirtazapine responsiveness in advance before the appearance of the drug effect until 4-6 weeks after administration of Mirtazapine.
The purpose of this study is 1. to determine whether genomic differences between drug responders and nonresponders predict the response of Mirtazapine and 2. to construct the prediction model for Mirtazapine treatment in depressed patients in order to aid to select the genetically matching drug.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
100
Mirtazapine administration for 6 weeks under therapeutic dose
Samsung Medical Center
Kangnam, Seoul, South Korea
RECRUITINGMirtazapine response at 2,4,6 weeks and adverse events (A/E) monitoring at 1,2,4,6 weeks
Time frame: 6 weeks
Biological value at 0 and 6 weeks
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.